MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Core Insights - Marker Therapeutics' shares have increased by approximately 114% over the past three months, primarily due to positive momentum surrounding its lead candidate, MT-601, which has enhanced investor confidence [1][7] Clinical Development - The phase I APOLLO study for MT-601 has shown promising results, with about 66% of patients with Non-Hodgkin Lymphoma achieving an objective response and 50% achieving a complete response [2][3] - The responses in the APOLLO study were durable, lasting from three to 24 months, with some patients maintaining benefits beyond six months, including responses extending over one year [2] - MT-601 also demonstrated a 78% response rate in patients with Hodgkin Lymphoma, leading the company to advance to the dose expansion phase for patients with relapsed diffuse large B cell lymphoma [3] Future Prospects - Additional clinical data from the APOLLO study is anticipated in the first half of 2026, which is expected to serve as a significant catalyst for the stock [3] - The company plans to initiate clinical studies for MT-601 targeting pancreatic cancer in the first half of 2026 [6] Financial Position - Marker Therapeutics has secured non-dilutive funding from various institutions, including the National Institutes of Health, to support the development of MT-601 and its Off-the-Shelf (OTS) program [10] - The company raised approximately $10 million through its at-the-market facility, extending its cash runway into 2026 and providing financial stability for ongoing clinical development [11] Manufacturing and Collaboration - Marker Therapeutics has entered into a strategic manufacturing collaboration with Cellipont to enhance the production capabilities of MT-601 [8] Additional Developments - The company has made progress with its OTS platform, having treated its first patient in a phase I RAPID study for MT-401, which was well-tolerated without side effects [9]